Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes.

@article{Arranz2013TreatmentOE,
  title={Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes.},
  author={Alicia Arranz and Christina Reinsch and Konstantinos Antonios Papadakis and Andreas Dieckmann and Una Rauchhaus and Ariadne Androulidaki and Vassiliki Zacharioudaki and Andrew N. Margioris and Christos Tsatsanis and Steffen Panzner},
  journal={Journal of controlled release : official journal of the Controlled Release Society},
  year={2013},
  volume={165 3},
  pages={163-72}
}
BACKGROUND AND AIMS CD40-CD40L interactions appear to play an important role in the pathogenesis of experimental colitis. We tested the effect and investigated the underlying mechanism of action of systemically administered antisense oligonucleotide (ASO) targeting CD40 formulated in amphoteric liposomes (nov038/CD40). The charge characteristics of the… CONTINUE READING